Company Overview and News

 
Evaluating Daqo New Energy

2018-01-31 seekingalpha
Daqo New Energy (DQ) is a Chinese based company focused on the production of pure polysilicon. Polysilicon is used for the manufacturing of solar panels. Daqo has become an attractive company due to their profit margins and low cost production in comparison to their competitors. We’re going to look at some qualitative aspects of Daqo, a quantitative analysis evaluating their intrinsic value, and some risks associated with a potential investment in Daqo New Energy.

 
China’s solar major GCL to get US$1 billion investment from Taiping Insurance

2017-11-21 scmp
Under a non binding agreement signed, Taiping Financial Holdings will lead a US$1 billion fund to buy new shares and convertible bonds

 
Review Of Solar Picks For Saudi Aramco And Lessons Learned

2017-08-04 seekingalpha
Six months ago, I investigated possible candidates that Saudi Aramco would be interested in given its plan to invest up to $5 billion in renewable energy firms.

 
With A $5 Billion War Chest, Which Renewable Energy Firms Will Saudi Aramco Invest In?

2017-02-16 seekingalpha
I looked at the top five ETFs in renewable energy and selected six companies for review of potential.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

13h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

13h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...